SAB Biotherapeutics reaffirmed its goal of completing enrolment in its pivotal Type 1 diabetes trial by the end of 2026. The company posted a third-quarter net loss of $22.3 million, against net income of $45.4 million a year earlier. Adult and adolescent groups in the Phase IIb SAFEGUARD trial of SAB-142 are fully enrolled, and screening of children aged 5 to 11 is under way. Top-line results are expected in the second half of 2027. The US Food and Drug Administration (FDA) granted SAB-142 Fast Track designation in October. A separate investigator-led Phase III study, PRISE, is expected to dose its first patient in the fourth quarter. Research and development spending rose to $18.1 million from $9 million. SAB ended September with $205 million in cash, equivalents and securities, which it expects to fund operations through 2028.

SAB Biotherapeutics reported a third-quarter net loss of $22.3 million, against net income of $45.4 million a year earlier, when warrant gains lifted results. The Miami-based company is developing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes. Cash and investment securities stood at $205.3 million on September 30, 2026, which the company says funds operations through 2028. Research spending rose to $18.1 million from $9.0 million, and general and administrative costs reached $7.8 million from $3.7 million. Adult and adolescent cohorts in the registrational SAFEGUARD study are fully enrolled, and the pediatric cohort is still enrolling. The company expects to complete enrolment of about 159 patients in the fourth quarter of 2026, with topline data in the second half of 2027. In October, the US Food and Drug Administration granted SAB-142 Fast Track designation for new-onset Stage 3 type 1 diabetes.